Mantis Biotech vs BioNTech

Side-by-side comparison of AI visibility scores, market position, and capabilities

BioNTech leads in AI visibility (88 vs 32)
Mantis Biotech logo

Mantis Biotech

EmergingBioTech

AI Clinical Trial Simulation

YC-backed AI company raised $48M Series A co-led by a16z Bio and GV in Feb 2026; builds digital twins of human physiology to generate diverse synthetic clinical trial populations, addressing chronic underrepresentation of women and minorities.

AI VisibilityBeta
Overall Score
D32
Category Rank
#1 of 1
AI Consensus
48%
Trend
up
Per Platform
ChatGPT
23
Perplexity
42
Gemini
27

About

Mantis Biotech is a YC-backed AI company that builds digital twins of human physiology to synthesize diverse, realistic clinical trial populations. The company addresses one of drug development's most persistent problems: clinical trials consistently underrepresent women, elderly patients, and minorities, producing efficacy data that fails to predict real-world outcomes across populations. Mantis's AI platform generates synthetic patient data that fills these representation gaps.

Full profile
BioNTech logo

BioNTech

LeaderLife Sciences & BioTech

mRNA Therapeutics

German mRNA pioneer co-developed COVID-19 vaccine with Pfizer; 20+ clinical programs in oncology and infectious disease;

AI VisibilityBeta
Overall Score
A88
Category Rank
#1 of 1
AI Consensus
52%
Trend
up
Per Platform
ChatGPT
80
Perplexity
86
Gemini
82

About

BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneered individualized neoantigen-specific immunotherapy and mRNA-based therapeutic approaches before co-developing the world's first authorized mRNA vaccine with Pfizer during the COVID-19 pandemic.\n\nBioNTech's pipeline spans over 20 clinical programs in oncology, infectious disease, and autoimmune conditions. Key assets include BNT111, an mRNA cancer vaccine for melanoma evaluated in combination with Regeneron's cemiplimab, as well as a suite of CAR-T, bispecific antibody, and mRNA-encoded cytokine programs. The company manufactures mRNA therapies at scale through its BioNTainer modular facilities deployable to emerging markets.\n\nBioNTech generated approximately €2.4 billion in revenue in 2024 and holds a robust cash position exceeding €17 billion, enabling sustained R&D investment. The company is recognized as one of the most pivotal biotech success stories of the 21st century, combining deep immunology science with scalable mRNA manufacturing to pursue a world where cancer is a manageable disease.

Full profile

AI Visibility Head-to-Head

32
Overall Score
88
#1
Category Rank
#1
48
AI Consensus
52
up
Trend
up
23
ChatGPT
80
42
Perplexity
86
27
Gemini
82
23
Claude
99
37
Grok
80

Key Details

Category
AI Clinical Trial Simulation
mRNA Therapeutics
Tier
Emerging
Leader
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Mantis Biotech
AI Clinical Trial Simulation
Only BioNTech
mRNA Therapeutics

Integrations

Only BioNTech

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.